Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of “Buy” from Analysts

Alto Neuroscience, Inc. (NYSE:ANRO) has earned an average recommendation of “Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have covered the stock in the last year is $35.00.

ANRO has been the subject of several research analyst reports. Rodman & Renshaw began coverage on shares of Alto Neuroscience in a research note on Friday, June 21st. They set a “buy” rating and a $43.00 price target for the company. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research report on Wednesday, June 12th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $32.00 price target on shares of Alto Neuroscience in a research report on Monday, March 25th.

Alto Neuroscience Trading Down 0.2 %

Shares of Alto Neuroscience stock opened at $14.96 on Tuesday. The stock’s fifty day moving average is $12.33. Alto Neuroscience has a 12-month low of $9.40 and a 12-month high of $24.00. The company has a quick ratio of 26.02, a current ratio of 26.02 and a debt-to-equity ratio of 0.05.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Tuesday, May 14th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.30). On average, research analysts anticipate that Alto Neuroscience will post -2.93 earnings per share for the current year.

Insider Transactions at Alto Neuroscience

In related news, insider Adam Savitz acquired 12,069 shares of the company’s stock in a transaction that occurred on Tuesday, July 9th. The shares were acquired at an average price of $12.60 per share, with a total value of $152,069.40. Following the acquisition, the insider now owns 36,920 shares of the company’s stock, valued at approximately $465,192. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Institutional Trading of Alto Neuroscience

Several institutional investors and hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. bought a new position in shares of Alto Neuroscience in the first quarter worth $21,267,000. Price T Rowe Associates Inc. MD bought a new position in Alto Neuroscience in the 1st quarter worth about $9,788,000. Vanguard Group Inc. purchased a new stake in shares of Alto Neuroscience in the 1st quarter valued at about $8,233,000. Jennison Associates LLC bought a new stake in shares of Alto Neuroscience during the 1st quarter valued at about $7,039,000. Finally, Artal Group S.A. purchased a new position in shares of Alto Neuroscience during the first quarter worth about $5,372,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.